GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Adaptive Biotechnologies
Adaptive Biotechnologies has developed a platform for sequencing the immune system. Its stock price is a bet on the application of this technology in diagnostics (for example, cancer detection) and drug development. The chart reflects the long and risky path from science to commercialization.
Share prices of companies in the market segment - Pharma immune
Adaptive is a biotech company specializing in immune system sequencing. Its segments are research services and clinical diagnostics. We classify it as part of the Pharma immune sector, and the chart below reflects the dynamics of the entire industry, where value is determined by the success of its platform.
Broad Market Index - GURU.Markets
Adaptive Biotechnologies is a biotech company that uses its immune receptor sequencing platform for diagnostics and drug development. It is a component of the GURU.Markets index. The chart below shows the market. See how Adaptive shares compare to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ADPT - Daily change in the company's share price Adaptive Biotechnologies
Shares of Adaptive Biotechnologies, which focuses on the immune system, are highly volatile. change_co tracks market reactions to research and partnership data. This metric is fundamental to building complex biotech risk assessment models on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
Adaptive Biotechnologies Corp. is a biotech company. This chart demonstrates the sector's extreme volatility. Comparison with ADPT, which focuses on immune system mapping, helps to assess it as a high-risk, R&D-dependent asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Adaptive Biotechnologies is a pioneer in immune system sequencing. Its technology is used for diagnostics and drug development. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting Adaptive's risks and potential.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Adaptive Biotechnologies
Adaptive is a biotech company specializing in sequencing immune system receptors. Its year-over-year performance reflects both the growth of its diagnostics business and investor confidence in the potential of its drug discovery platform.
Annual dynamics of market capitalization of the market segment - Pharma immune
Adaptive Biotechnologies Corp. is a biotech company specializing in immune system sequencing. Its platform has enormous potential for both diagnostics and drug development. This chart shows how the market views its innovative yet capital-intensive technology and its path to profitability.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Adaptive, with its immune system mapping platform, is a speculative bet on the future of medicine. Its stock price isn't tied to economics, but rather driven by scientific breakthroughs and partnerships. The chart tells the story of investors' belief that understanding immunity will revolutionize diagnostics and treatment.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Adaptive Biotechnologies
Adaptive, a biotech company specializing in immune system sequencing, shows monthly fluctuations in its chart, reflecting the adoption of its diagnostic tests and progress in developing drugs based on its platform.
Monthly dynamics of market capitalization of the market segment - Pharma immune
This chart reflects the dynamics of the biotech sector. For Adaptive, with its immune system sequencing platform, it's the backdrop. Its movements illustrate how the company is monetizing its unique technology through diagnostics and partnerships with pharmaceutical companies.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Adaptive Biotechnologies is developing a platform for sequencing the immune system. Like many biotech companies in the research stage, its shares are highly volatile and dependent on news of scientific breakthroughs and partnerships. The company's performance is largely unrelated to overall market trends, driven by its own catalysts.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Adaptive Biotechnologies
Adaptive Biotechnologies Corp. is a company specializing in sequencing immune system receptors for diagnostics and drug development. Its weekly stock price is volatile and depends on progress in the commercialization of its diagnostic tests and news of partnerships with pharmaceutical companies.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Adaptive, with its unique immune system mapping technology, is charting its own trajectory, distinct from the broader biotech sector. News of partnerships and the commercialization of its tests are the main drivers. The chart clearly shows how its breakthrough science is giving its stock a life of its own.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Adaptive Biotechnologies is developing a platform for mapping the immune system. This is a breakthrough technology, but it's currently unprofitable. The company's shares are highly volatile, reflecting hopes for future discoveries. The chart will reveal this disconnect from the market.
Market capitalization of the company, segment and market as a whole
ADPT - Market capitalization of the company Adaptive Biotechnologies
Adaptive Biotechnologies' market capitalization reflects investor faith in its immune system sequencing platform. Its volatile price chart reflects how the market perceives the potential of this technology for disease diagnosis and drug development. It's a high-risk bet that mapping the immune system will be the key to the future of medicine.
ADPT - Share of the company's market capitalization Adaptive Biotechnologies within the market segment - Pharma immune
Adaptive Biotechnologies holds a leading share of the immune system sequencing market. Its market capitalization is based on the potential of its platform for disease diagnostics, cancer monitoring, and immune-based drug discovery.
Market capitalization of the market segment - Pharma immune
The graph below shows the market capitalization of the biotech sector. Adaptive Biotechnologies is a leader in immune system sequencing. Its platform allows for the "reading" of T and B cells, opening up enormous opportunities in diagnostics and drug development. The growth of this market reflects a revolution in our understanding of immunity, and Adaptive is at the forefront.
Market capitalization of all companies included in a broad market index - GURU.Markets
Adaptive Biotechnologies has developed a platform for sequencing the immune system. Its market capitalization is based on the technology's potential for diagnostics and drug development. The chart below shows the economic weight of companies that "read" the human body's code.
Book value capitalization of the company, segment and market as a whole
ADPT - Book value capitalization of the company Adaptive Biotechnologies
Adaptive Biotechnologies' book value is determined by its unique immunomedicine platform for sequencing immune system receptors, used in diagnostics and drug development. The chart shows how the company is investing in this complex technology, turning scientific data into potential diagnostic products and therapeutics.
ADPT - Share of the company's book capitalization Adaptive Biotechnologies within the market segment - Pharma immune
Adaptive Biotechnologies is mapping the immune system. The chart shows its share of real R&D assets. These include its high-throughput sequencing labs, which translate biological information into digital data, creating a platform for diagnostics and therapeutics.
Market segment balance sheet capitalization - Pharma immune
Adaptive Biotechnologies is an immune medicine company, and its model is intellectually rather than capital-intensive. Its value lies in its immune receptor sequencing platform, not its manufacturing facilities. Compared to the broader biotech sector, its "light" balance sheet is typical of companies focused on data and R&D.
Book value of all companies included in the broad market index - GURU.Markets
Adaptive Biotechnologies' assets are not drugs, but a unique platform for sequencing and analyzing the human immune system. The company's balance sheet reflects the value of this massive database of immune receptors and its diagnostic tests. The chart shows the capital invested in "mapping" the human immune system.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Adaptive Biotechnologies
Adaptive Biotechnologies is a company specializing in immune system mapping. Its market value is based on the potential of its platform for diagnostics and drug development. Investors are paying for the unique technology and data, not the lab equipment, creating a huge gap with its book value.
Market to book capitalization ratio in a market segment - Pharma immune
Adaptive Biotechnologies has developed a platform for sequencing the immune system. Its value lies in its unique technology and data. This chart shows how the market valuation, based on the platform's potential for diagnostics and drug development, far exceeds the cost of its laboratory equipment.
Market to book capitalization ratio for the market as a whole
Adaptive Biotechnologies has developed a platform for sequencing the immune system. Its market capitalization is based on the potential of this technology for diagnostics and drug discovery. The chart shows the enormous premium the market pays for a breakthrough scientific platform capable of changing approaches to medicine, compared to its tangible assets.
Debts of the company, segment and market as a whole
ADPT - Company debts Adaptive Biotechnologies
Adaptive Biotechnologies uses its unique platform to sequence immune system receptors, which has applications in diagnostics and drug development. Developing such cutting-edge technology requires significant investment in research. This chart shows how the company raises capital to fund its scientific and commercial activities.
Market segment debts - Pharma immune
Adaptive Biotechnologies specializes in sequencing immune system receptors for use in diagnostics and drug development. This is a cutting-edge scientific field that requires significant investment. This chart shows how the company funds its unique technology platform and how its financial strategy reflects the commercialization stage of its products.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Adaptive Biotechnologies
Adaptive Biotechnologies uses its immune system sequencing platform to develop diagnostic and therapeutic products. This chart shows the biotech company's financial position during the commercialization and research stages. Capital deployment reflects the balance between revenue from diagnostic tests and significant investments in drug development.
Market segment debt to market segment book capitalization - Pharma immune
Adaptive Biotechnologies uses its immune system mapping platform for diagnostics and drug development. This chart shows the debt burden in the innovative biotech sector. It helps understand how the company funds its cutting-edge research and how its financial structure compares to other players at the intersection of technology and medicine.
Debt to book value of all companies in the market
Adaptive Biotechnologies, an innovative biotech company, relies on venture capital to fund its operations. The chart shows the overall debt burden for the entire economy. It emphasizes that while the rest of the market focuses on interest rates, companies like Adaptive depend on investors' faith in their technology and on successful research.
P/E of the company, segment and market as a whole
P/E - Adaptive Biotechnologies
For Adaptive Biotechnologies, which uses the immune system for diagnostics and treatment, this chart is a valuation of its unique platform. The high price per dollar of potential revenue suggests that investors see revolutionary potential in its technology. The momentum reflects progress in the commercialization of diagnostic tests and drug development.
P/E of the market segment - Pharma immune
This chart reflects the average valuation for the speculative biotech sector—a benchmark for Adaptive. For investors, it serves as a benchmark, reflecting the overall level of optimism in the industry. Against this backdrop, one can gauge expectations for Adaptive's unique platform for "reading" the immune system, which can be applied across various fields of medicine.
P/E of the market as a whole
Adaptive Biotechnologies is using its immune receptor sequencing platform for diagnostics and drug development. This cutting-edge science has enormous potential. This chart of overall biotech investor risk appetite shows how willing they are to fund long-term R&D platforms that could revolutionize medicine but are not yet profitable.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Adaptive Biotechnologies
Adaptive Biotechnologies has developed a platform for sequencing immune system receptors, opening up new possibilities in disease diagnosis and treatment. The company's valuation is a bet on its technology. This chart reflects analysts' confidence in the commercial potential of its diagnostic tests and developments in oncology and autoimmune diseases.
%20P%2FE%20Adaptive%20Biotechnologies&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Adaptive-Biotechnologies&v=1772513568525 "Chart of the company's future (projected) P/E Adaptive Biotechnologies")
Future (projected) P/E of the market segment - Pharma immune
Adaptive Biotechnologies is a company specializing in mapping the immune system. Its platform is used for diagnostics and the development of new treatments. Its valuation, relative to other biotech companies, reflects the high expectations for its technology. Investors are betting that understanding the immune response will be key to treating cancer and autoimmune diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513568545 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Adaptive Biotechnologies is a company that has developed a platform for sequencing immune system receptors. The technology is used in diagnostics and drug development. This chart shows the overall risk appetite of investors. For companies at the forefront of science like Adaptive, market optimism is important for funding research and commercializing complex products.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513568588 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Adaptive Biotechnologies
Adaptive Biotechnologies is a company that has developed a platform for sequencing immune system receptors (T- and B-cells). Financial results reported here depend on the use of its technology for research and clinical diagnostics, such as cancer monitoring. This represents the cutting edge of immune medicine.
Profit of companies in the market segment - Pharma immune
Adaptive Biotechnologies is using its immune receptor sequencing platform to develop new diagnostics and therapeutics. This chart reflects the financial health of the immunopharmacology sector. It shows how commercially successful this cutting-edge field of medicine is, or whether it remains a focus on fundamental research.
Overall market profit
Adaptive Biotechnologies has developed a platform for sequencing immune system receptors. The technology is used in both diagnostics and drug development. It's a knowledge-intensive business whose value is determined by scientific breakthroughs and commercialization. Macroeconomic cycles, visible in this graph, influence it only indirectly, through the investment climate.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Adaptive Biotechnologies
Adaptive Biotechnologies has developed a unique platform for mapping the human immune system. This opens up new possibilities in diagnostics and drug discovery. The future revenue forecast represents a long-term bet on the commercialization of this technology. The graph shows how much analysts believe the company will be able to monetize its data and scientific discoveries.
%20profit%20of%20the%20company%20Adaptive%20Biotechnologies&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Adaptive-Biotechnologies&v=1772513568661 "Graph of future (projected) profit of the company Adaptive Biotechnologies")
Future (predicted) profit of companies in the market segment - Pharma immune
Adaptive Biotechnologies has developed a platform for sequencing immune system receptors (T and B cells) on a massive scale. The technology is used in diagnostics (for example, to detect residual disease in cancer) and drug development. This graph shows forecasts for this segment, illustrating the enormous expectations for immune medicine and the potential of Adaptive's platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513568682 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Adaptive Biotechnologies is using its immune platform to develop diagnostic tests and therapeutics. This projected profit curve is impacting biotech funding. Market optimism and economic growth facilitate capital raising for long-term research and development that leads to medical breakthroughs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513568712 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Adaptive Biotechnologies
Adaptive Biotechnologies has developed a platform for sequencing the immune system. This chart shows how investors estimate the potential revenue from its diagnostic tests and partnerships with pharmaceutical companies, betting on a breakthrough in personalized medicine.
P/S market segment - Pharma immune
Adaptive Biotechnologies is a company that uses its immunosequencing platform to decipher the adaptive immune system. This chart shows the average valuation in the immunopharmaceutical sector. It reflects the premium investors are willing to pay for a technology that could revolutionize the diagnosis and treatment of cancer and autoimmune diseases.
P/S of the market as a whole
Adaptive Biotechnologies Corporation has developed a platform for sequencing immune system receptors, enabling its use in diagnostics and drug development. The company's revenue comes from research services and clinical diagnostics. This chart helps assess the market's appreciation for this unique technology platform at the intersection of biotech and AI.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Adaptive Biotechnologies
Adaptive Biotechnologies specializes in sequencing immune system receptors. Future revenue depends on the adoption of its diagnostic tests (for example, for cancer monitoring) and success in drug development. The chart reflects investors' confidence in the potential of its platform to revolutionize diagnostics and therapeutics.
%20P%2FS%20Adaptive%20Biotechnologies&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Adaptive-Biotechnologies&v=1772513568737 "The graph of the company's future (projected) P/S Adaptive Biotechnologies")
Future (projected) P/S of the market segment - Pharma immune
Adaptive Biotechnologies is a company that has developed a platform for sequencing immune system receptors (T and B cells). This technology is used for diagnostics, disease monitoring, and drug development. This chart shows how investors evaluate the commercial potential of this unique immune platform compared to other biotech companies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513568771 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
This illustrates the overall sentiment of investors in the field of personalized medicine. For Adaptive Biotechnologies, a company that maps the immune system, this reflects faith in the future of diagnostics and therapeutics. Market optimism is helping fund the development of tests that could revolutionize the treatment of cancer and autoimmune diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513568788 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial biotech company that uses its immune receptor sequencing platform to develop tests and therapeutics. This chart shows revenue from diagnostic tests and research services. Revenue growth reflects the deployment of their technology in cancer monitoring and immunology research.
Sales of companies in the market segment - Pharma immune
Adaptive Biotechnologies is a company that uses its immunosequencing platform to map the adaptive immune system. This graph shows growth in the immunopharmacology sector. Adaptive's technologies are used in both diagnostics (for example, to track residual cancer) and drug development, placing the company at the forefront of biomedicine.
Overall market sales
Adaptive Biotechnologies is developing a platform for sequencing the immune system. Its technologies are used in drug research and development. Demand depends on funding in the biotech sector. The overall economic situation, shown in this chart, influences investor appetite and pharmaceutical company budgets for advanced research tools.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Adaptive Biotechnologies
Adaptive Biotechnologies has developed a platform for sequencing immune system receptors (T- and B-cells), which has applications in diagnostics and drug development. Future revenue depends on the commercialization of diagnostic tests and partnerships with pharmaceutical companies. This chart reflects analysts' confidence in the potential of the company's technology to transform medicine.
%20sales%20of%20the%20company%20Adaptive%20Biotechnologies&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Adaptive-Biotechnologies&v=1772513568887 "Schedule of future (projected) sales of the company Adaptive Biotechnologies")
Future (projected) sales of companies in the market segment - Pharma immune
Adaptive Biotechnologies is a company using its immune receptor sequencing platform to develop diagnostic and therapeutic products. This forecast outlines expectations for the immune pharmaceutical sector, reflecting the growing interest in immunology for the diagnosis and treatment of cancer and autoimmune diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513568888 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Adaptive Biotechnologies Corp. specializes in immune receptor sequencing technologies. Its platform is used in drug research and development. The company's growth depends on investment in biopharmaceuticals. This graph, reflecting the overall economic situation, influences R&D funding, which drives demand for Adaptive's cutting-edge research tools.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513568924 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Adaptive Biotechnologies
Adaptive Biotechnologies is using its immune system sequencing platform to develop new diagnostics and treatments. The chart illustrates the scale of investment in this breakthrough technology. The profit margin is currently negative, as revenue from research contracts is reinvested in the development of future diagnostic tests.
Market segment marginality - Pharma immune
Adaptive Biotechnologies uses its immunosequencing platform for diagnostics and the development of new treatments. Profitability depends on the commercialization of diagnostic tests and the success of drug development. This chart illustrates the company's operational structure, which combines services and R&D, compared to other biotech firms.
Market marginality as a whole
Adaptive Biotechnologies specializes in mapping the human immune system to develop new diagnostics and treatments. This overall market profitability chart is irrelevant to the company. Its potential profitability lies in the uniqueness of its platform and its ability to create breakthrough products in oncology and autoimmune diseases.
Employees in the company, segment and market as a whole
Number of employees in the company Adaptive Biotechnologies
Adaptive Biotechnologies is a company that uses its immune receptor sequencing platform to develop new diagnostics and therapeutics. The chart shows the team's scientists and bioinformatics specialists. The growth reflects investment in this cutting-edge technology.
Share of the company's employees Adaptive Biotechnologies within the market segment - Pharma immune
Adaptive Biotechnologies has developed a platform for sequencing immune system receptors, opening up new possibilities in diagnostics and treatment. This chart shows the percentage of leading immunologists, bioinformaticians, and machine learning specialists the company attracts in its niche, reflecting its concentration of talent at the intersection of biotech and IT.
Number of employees in the market segment - Pharma immune
Adaptive Biotechnologies Corp. is a company using its immunomedicine platform for T- and B-cell receptor sequencing to develop new diagnostics and therapeutics for oncology and autoimmune diseases. This chart reflects employment growth in the immune pharmaceutical sector, demonstrating how a deeper understanding of the immune system is opening new horizons in medicine.
Number of employees in the market as a whole
Adaptive Biotechnologies has developed a platform for sequencing immune system receptors. Their technologies are used for diagnostics, monitoring, and the development of new treatments. This is a highly knowledge-intensive business at the intersection of biotechnology and IT. It creates unique jobs for scientists and bioinformatics specialists, forming the intellectual vanguard of the economy.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies has developed a platform for sequencing immune system receptors. This chart shows how the market values this breakthrough science. The very high market capitalization per employee reflects the enormous potential of their technology for diagnostics, cancer monitoring, and drug development. The value lies in the data and algorithms.
%20of%20the%20company%20Adaptive%20Biotechnologies%20(ADPT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Adaptive-Biotechnologies-ADPT&v=1772513569026 "Chart of market capitalization per employee (in thousands of dollars) of the company Adaptive Biotechnologies (ADPT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Adaptive Biotechnologies (ADPT) is a biotech company using its immunomedical platform to sequence immune system receptors (T and B cells) for diagnostics and therapeutics. This chart shows the industry average cost per employee. It helps assess how much the market values their unique R&D platform per scientist.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513569048 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Adaptive Biotechnologies is a biotech company that sequences immune system receptors to develop diagnostics and therapeutics. This chart shows the market-wide cost per employee, highlighting the enormous value of this cutting-edge scientific platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513569078 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies is a company specializing in immune system (T-cell) mapping. It's a platform at the intersection of biotech and IT. This graph likely represents the company's per-employee loss, as it heavily invests in R&D and data collection. It reflects the cost of creating a unique immune database.
%20Chart%20Adaptive%20Biotechnologies%20(ADPT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Adaptive-Biotechnologies-ADPT&v=1772513569082 "Company Profit Per Employee (in thousands of dollars) Chart Adaptive Biotechnologies (ADPT)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Adaptive (ADPT) is a "biotech" that uses AI to "map" the immune system. This chart shows the benchmark for "Immune Pharma" (R&D). The average profit per employee in this sector is *negative*. This benchmark reflects the "burn" of money. The entire sector is an R&D race, spending billions on AI engineers and scientists in hopes of a future breakthrough.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513569093 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Adaptive Biotechnologies specializes in immune system (T-cell) sequencing for R&D (in partnership with Genentech) and diagnostics (clonoSEQ). This is "techbio." This chart shows how successfully the company is monetizing its unique platform. Profit (or loss) per employee reflects the balance between expensive R&D and diagnostic revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513569107 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies is a company that uses its immunomedicine platform to develop drugs and diagnostics. This chart illustrates the monetization of cutting-edge biotechnologies. It reflects the company's ability to translate deep scientific knowledge about the immune system into commercial products and services.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Adaptive-Biotechnologies-ADPT&v=1772513569131 "Sales chart per company employee Adaptive Biotechnologies (ADPT)")
Sales per employee in the market segment - Pharma immune
Adaptive Biotechnologies specializes in "reading" and mapping the immune system (T cells) for diagnostics and drug development. This is high-tech biology. This chart shows the average revenue per employee in the segment. It helps evaluate how effectively Adaptive monetizes its platform compared to competitors.
Sales per employee for the market as a whole
Adaptive Biotechnologies is a biotech company specializing in immune system mapping. They have two segments: R&D services for pharmaceutical companies and test development. This graph shows how effectively their highly qualified scientists and engineers generate revenue from their services and diagnostic products, monetizing their unique platform.
Short shares by company, segment and market as a whole
Shares shorted by company Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies offers a platform for sequencing the immune system (T cells) for diagnostics (cancer) and drug development. The technology is complex, and the path to profitability is unclear. This chart demonstrates the high level of investor skepticism regarding the commercialization of the technology and its true clinical value compared to other methods.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Adaptive-Biotechnologies-ADPT&v=1772513569151 "Short Shares Chart for the Company Adaptive Biotechnologies (ADPT)")
Shares shorted by market segment - Pharma immune
Adaptive Biotechnologies uses its platform to map the genetic code of the immune system (T-cells). They apply this technology to oncology (diagnostics) and drug development. This chart reflects the total short position in the biotech sector. High values indicate general investor skepticism regarding the commercialization of complex diagnostic platforms and their true profitability.
Shares shorted by the overall market
Adaptive (ADPT) is a biotech focused on the immune system. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs dependent on financing. This pessimism, visible on the chart, threatens the capital needed by ADPT.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies uses its platform to "read" the immune system, which is used in oncology and R&D. It's a breakthrough technology, but so far, it's largely unprofitable. This chart measures investor confidence in the future of this platform. It shows when the hype (overbought) or despair (oversold) regarding the commercialization of their tests reaches its limit.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Adaptive-Biotechnologies-ADPT&v=1772513569202 "RSI 14 indicator chart for the company's stock Adaptive Biotechnologies (ADPT)")
RSI 14 Market Segment - Pharma immune
Adaptive Biotechnologies is a biotech company specializing in "reading" and mapping the immune system (T cells and B cells). Their platform is used for diagnostics (such as clonoSEQ) and drug development. This chart reflects overall sentiment in the biotech sector, helping to assess how the market views this speculative industry.
RSI 14 for the overall market
Adaptive Biotechnologies (ADPT) is a biotech company. Like everything in its sector, it's critically dependent on this timeline. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ADPT (Adaptive Biotechnologies)
Adaptive Biotechnologies (ADPT) has developed a platform for sequencing and "reading" the immune system. This chart shows the average target price. It reflects analysts' opinions on the growth potential of their diagnostic tests (especially in oncology) and revenue from partnerships with pharmaceutical companies.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ADPT-Adaptive-Biotechnologies&v=1772513569258 "A chart showing analyst consensus forecasts for the expected stock price. ADPT (Adaptive Biotechnologies)")
The difference between the consensus estimate and the actual stock price ADPT (Adaptive Biotechnologies)
Adaptive Biotechnologies is a biotech platform that sequences (maps) the immune system (T-cells, B-cells). The company sells R&D services to the pharmaceutical industry and diagnostics (clonoSEQ). This chart shows the difference between the consensus forecast and the price. It reflects analysts' confidence in the scientific potential of this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ADPT-Adaptive-Biotechnologies&v=1772513569291 "A chart showing the difference between the consensus forecast and the actual stock price. ADPT (Adaptive Biotechnologies)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Adaptive Biotechnologies is a company using its immune medicine platform to develop highly accurate diagnostic tests (clonoSEQ for blood cancer) and discover new drugs. This chart shows general expectations for the immune pharma sector. It reflects whether experts believe in the potential of "reading" the immune system.
Analysts' consensus forecast for the overall market share price
Adaptive Biotechnologies is a company specializing in reading the immune system. Their technology is used for diagnostics (for example, cancer monitoring) and drug development. This chart shows the company's overall risk appetite. As a pioneer in complex biotechnology, Adaptive's overall market optimism is crucial for funding long-term research and maintaining a high valuation.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Adaptive Biotechnologies
Adaptive Biotechnologies is a company at the intersection of immunology and AI. Their platform (immunoSEQ) is capable of reading and mapping trillions of immune system cells (T cells, B cells). This chart is an assessment of their R&D platform. It reflects their ability to monetize this data by selling it to pharmaceutical companies for drug development, and their own potential for developing diagnostic tests (clonoSEQ).
AKIMA Market Segment Index - Pharma immune
Adaptive (ADPT) is a biotech pioneer in immune medicine; the company uses its TCR/BCR sequencing platform for diagnostics (clonoSEQ for blood cancer) and R&D. This summary metric measures R&D. The graph shows the segment average. This benchmark: how does this unique R&D platform (immune sequencing) differentiate ADPT from the average pharma company?
The AKIM Index for the overall market
Adaptive Biotechnologies is a pioneer in immune system sequencing. The company develops diagnostic tests (clonoSEQ) and drug discovery. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative scientific story, driven by the laws of biotech, compares to overall economic trends.
